Journal of medical imaging and radiation oncology · 2025
The Role of PET-CT in Cancer Patients Aged 85 and Older: A Tool for Precision or Overutilisation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaya Efkan, Tanriverdi Ozgur, Barutca Sabri
Аннотация
INTRODUCTION: This study investigates the role of positron emission tomography-computed tomography in the treatment decision-making process for cancer patients aged 85 years and older.
METHODS: Retrospective study including 137 patients. Patients aged ≥ 85 years with histopathological solid malignancy. Demographic characteristics and comorbidities as well as performance status (ECOG), tumour characteristics, imaging modalities and treatment choices were variables. Patients were categorised according to PET-CT use, and statistical analyses including Mann-Whitney U test, Bonferroni correction and binary logistic regression were performed to identify independent predictors of PET-CT use.
RESULTS: The majority of patients had ECOG 2 (69%), thoracic (32%) cancer and metastatic (70%) at diagnosis, with a median age of 89 years (range: 85-99). Comorbidities were common (73%), and the most common organ dysfunctions were renal (25%) and heart failure (24%). PET-CT was performed in 47% of the patients. PET-CT was predominantly used in patients with metastatic disease, those who had received radiotherapy and those who were given best supportive care. However, patients undergoing PET-CT had significantly lower rates of curative treatment (3% vs. 18%, p = 0.0016). Binary logistic regression identified best supportive care decision as the only independent predictor of PET-CT use.
CONCLUSIONS: The findings indicated that PET-CT is commonly used for staging in patients who are ultimately managed with palliative care. Future research should address the cost-effectiveness of PET-CT, appropriate imaging indications, and its impact on cancer-related outcomes.
METHODS: Retrospective study including 137 patients. Patients aged ≥ 85 years with histopathological solid malignancy. Demographic characteristics and comorbidities as well as performance status (ECOG), tumour characteristics, imaging modalities and treatment choices were variables. Patients were categorised according to PET-CT use, and statistical analyses including Mann-Whitney U test, Bonferroni correction and binary logistic regression were performed to identify independent predictors of PET-CT use.
RESULTS: The majority of patients had ECOG 2 (69%), thoracic (32%) cancer and metastatic (70%) at diagnosis, with a median age of 89 years (range: 85-99). Comorbidities were common (73%), and the most common organ dysfunctions were renal (25%) and heart failure (24%). PET-CT was performed in 47% of the patients. PET-CT was predominantly used in patients with metastatic disease, those who had received radiotherapy and those who were given best supportive care. However, patients undergoing PET-CT had significantly lower rates of curative treatment (3% vs. 18%, p = 0.0016). Binary logistic regression identified best supportive care decision as the only independent predictor of PET-CT use.
CONCLUSIONS: The findings indicated that PET-CT is commonly used for staging in patients who are ultimately managed with palliative care. Future research should address the cost-effectiveness of PET-CT, appropriate imaging indications, and its impact on cancer-related outcomes.